Skip to main content

Table 1 Dose-toxicity relationship for each clinical study

From: Assessment of various continual reassessment method models for dose-escalation phase 1 oncology clinical trials: using real clinical data and simulation studies

Study Dose DLTs Number of patients evaluable for DLT Proportion of patients who experienced a DLT P (DLT) for true dose toxicity curve
AZD3514 250 mg QD 0 6 0% 0%
500 mg QD 0 6 0% 0%
1000 mg QD 1 6 17% 17%
1000 mg BID 3 6 50% 50%
2000 mg BID 4 4 100% 100%
AZD1208 120 mg QD 0 3 0% 0%
240 mg QD 0 3 0% 0%
480 mg QD 0 3 0% 0%
700 mg QD 1 4 25% 25%
900 mg QD 2 3 67% 67%
AZD1480 15 mg BIDa 0 4 0% 0%
20 mg BID 1 5 20% 20%
30 mg BID 1 5 20% 20%
35 mg BID 2 3 67% 67%
45 mg BID 0 2 0% 67%
AZD4877 2 mg twice weekly 0 3 0% 0%
4 mg twice weekly 0 3 0% 0%
7 mg twice weekly 0 3 0% 0%
11 mg twice weekly 0 6 0% 0%
15 mg twice weekly 2 2 100% 100%
  1. aTaken from another study on AZD1480
  2. BID: twice daily; QD: once daily